InsiderTrades

Form 4 for PYXS Pyxis Oncology, Inc.

Accepted 2023-09-13 00:00:00 ET · period of report 2023-09-11 · accession 0001209191-23-049366 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
M 2023-09-13 2023-09-11+ PYXS Sullivan Lara Pres, CEO, Dir S - Sale $2.27 -27.9K 2.60M -1% -$63.3K
2023-09-13 2023-09-13 PYXS Sullivan Lara Pres, CEO, Dir F - Tax $2.13 -184.7K 2.41M -7% -$393.5K

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2023-09-13 S D 3,000 $2.27 2,597,265 D — — (F1) Reflects sales of common stock executed in multiple transactions. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected within the ranges set forth in footnotes 2 through 4 of this Form 4. (F4) The transaction was executed in multiple trades in prices ranging from $2.25 to $2.34.
2 Common Common Stock 2023-09-13 F D 184,742 $2.13 2,412,523 D — — (F5) Represents shares withheld to cover taxes due upon the vesting of certain restricted stock units.
3 Common Common Stock 2023-09-11 S D 20,000 $2.27 2,605,182 D — — (F2) The transaction was executed in multiple trades in prices ranging from $2.13 to $2.36. (F1) Reflects sales of common stock executed in multiple transactions. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected within the ranges set forth in footnotes 2 through 4 of this Form 4.
4 Common Common Stock 2023-09-12 S D 4,917 $2.25 2,600,265 D — — (F1) Reflects sales of common stock executed in multiple transactions. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected within the ranges set forth in footnotes 2 through 4 of this Form 4. (F3) The transaction was executed in multiple trades in prices ranging from $2.21 to $2.30.